FGF2

aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update

Retrieved on: 
星期四, 五月 2, 2024
FGFR4, Patient, EAP, ATS, FGF2, Investment, Safety, Poster, Research, Sarcoidosis, PDT, Conference, Biologics license application, ILD, ATyr Pharma, BLA, Small RNA, Clinical trial, American Thoracic Society, SAN, Pharmaceutical industry

SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced first quarter 2024 results and provided a corporate update. 

Key Points: 
  • Ended the first quarter 2024 with $87.7 million in cash, cash equivalents, restricted cash and investments.
  • SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced first quarter 2024 results and provided a corporate update.
  • Based on current enrollment projections, the Company anticipates completing enrollment in the study in the second quarter of 2024.
  • G&A Expenses: General and administrative expenses were $3.5 million for the first quarter 2024.

aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update

Retrieved on: 
星期四, 三月 14, 2024
PDT, Research, Conference, Interest, ATS, Biologics license application, Patient, SAN, Howard University, Knowledge, EAP, ATyr Pharma, EDT, NRP2, American Thoracic Society, Downstream, Investment, Clinical trial, Small RNA, Neuropilin, Myelocyte, Safety, Sarcoidosis, Immune system, FGF2, FGFR4, BLA, Pharmaceutical industry

SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2023 results and provided a corporate update.

Key Points: 
  • SAN DIEGO, March 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced fourth quarter and full year 2023 results and provided a corporate update.
  • Based on current enrollment projections, the Company anticipates completing enrollment in the study in the second quarter of 2024.
  • Interested parties may access the call by registering here in order to obtain a dial in, personalized passcode and webcast information.
  • Links to a live audio webcast and replay may be accessed on the aTyr website Events page at: http://investors.atyrpharma.com/events-and-webcasts .

RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)

Retrieved on: 
星期二, 十二月 5, 2023
Health, Communications, Clinical Trials, Pharmaceutical, Publishing, Optical, Biotechnology, Yoshi, Intravitreal injection, Safety, Visual acuity, Retina, Royal college, Anatomy, Risk, Exudate, Anti-VEGF, FGF2, Patient, P, Choroidal neovascularization, Aptamer, Eye, Therapy, Blood, Growth factor, Royal College of Ophthalmologists, Paratriathlon, NAMD, SUSHI, Fibrosis, Pharmaceutical industry, D.S

TEMPURA is an investigator-sponsored, single-center, open-label, 4-month study of umedaptanib pegol in five treatment-naïve nAMD patients.

Key Points: 
  • TEMPURA is an investigator-sponsored, single-center, open-label, 4-month study of umedaptanib pegol in five treatment-naïve nAMD patients.
  • Throughout these studies umedaptanib pegol was safe, well tolerated, and effective to treat nAMD patients with no or short history of anti-VEGF treatment.
  • In nAMD patients with a long history of anti-VEGF treatment, umedaptanib pegol showed no additional benefit of monotherapy or the combination over Eylea®.
  • Notably, visual acuity decreased slightly in patients who switched from anti-VEGF (Eylea®) to umedaptanib pegol in the RAMEN study.

BioBetter Pioneers Cultivated Meat Future with Molecular Farming

Retrieved on: 
星期二, 九月 12, 2023
Genetic distance, University of Michigan Business Engagement Center, Insulin, JVP, Hope, Innovation, Jerusalem Venture Partners, Bioreactor, Yaari, Ministry, Plant, Parity, FGF2, The Good Food Institute, Risk, USD250, HACCP, Meat, Good Food, Conference, GF, Safety, Fine chemical, Agriculture, Pharmaceutical industry, Health, GFS

KIRYAT SHEMONA, Israel, Sept. 12, 2023 /PRNewswire/ -- FoodTech start-up BioBetter, Ltd., opens its first food-grade pilot facility to accelerate the production of key growth factors for the cultivated meat industry. The company has pioneered a unique protein manufacturing platform for producing growth factors (GFs) using tobacco plants as self-sustained, animal-free bioreactors.

Key Points: 
  • Helping cultivated meat companies offer affordable and accessible products to consumers, BioBetter is revolutionizing the future of cellular agriculture with its innovative molecular farming-based production platform.
  • Currently, cultivated meat production processes are relatively expensive, making it a challenge to scale up and reach price parity with animal-based counterparts.
  • "Cultivated meat is still very expensive in comparison to conventional meat and the key is to reduce the growth medium costs to a minimum," explains Amit Yaari, Ph.D., CEO of BioBetter.
  • The company also is an active member of the Israeli Cultivated Meat Consortium, which unites academic institutions, large companies, and start-ups to collaboratively advance the field of cultivated meat.

Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill

Retrieved on: 
星期三, 八月 23, 2023
Hair, Collagen, Stem cell factor, Face, Ki-67, Oxygen, Survival, Nail, Hair follicle, DHT, Multimedia, Signal, Hair loss, Neck, Scalp, GHK, Capillary, Plasma, FGF2, Peptide, Blood, Testosterone, Microcirculation, Biotin, Health, Exosome, Human, Melanocyte, SCF, Saliva, Wound healing, Cosmetics, Dietary supplement, Vaccine, Copper, Sulfur, Minoxidil

SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill.

Key Points: 
  • SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill.
  • HAIRNA Exosome Hair Fill is developed with Maypharm's exclusive technology for scalp rejuvenation and hair growth.
  • In addition to HAIRNA Exosome Hair Fill, Maypharm has launched such popular human stem cell products such as 2XSOME for face and neck.
  • Whether you are looking to improve your appearance or to regain self-confidence, HAIRNA Exosome Hair Fill is a solution that is hard to beat.

Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill

Retrieved on: 
星期三, 八月 23, 2023
Hair, Collagen, Stem cell factor, Face, Ki-67, Oxygen, Survival, Nail, Hair follicle, DHT, Signal, Hair loss, Neck, Scalp, GHK, Capillary, Plasma, FGF2, Peptide, Blood, Testosterone, Microcirculation, Biotin, Health, Exosome, Human, Melanocyte, SCF, Saliva, Wound healing, Cosmetics, Dietary supplement, Vaccine, Copper, Sulfur, Minoxidil

SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill.

Key Points: 
  • SEOUL, South Korea and NEW YORK, Aug. 23, 2023 /PRNewswire/ -- Maypharm Launches the world first Adipose Stem Cell Exosome hair filler, HAIRNA Exosome Hair Fill.
  • HAIRNA Exosome Hair Fill is developed with Maypharm's exclusive technology for scalp rejuvenation and hair growth.
  • In addition to HAIRNA Exosome Hair Fill, Maypharm has launched such popular human stem cell products such as 2XSOME for face and neck.
  • Whether you are looking to improve your appearance or to regain self-confidence, HAIRNA Exosome Hair Fill is a solution that is hard to beat.

BioBetter Lands USD10M Funding to Relieve Cultivated Meat's Bottleneck Using Tobacco Plants

Retrieved on: 
星期三, 九月 7, 2022
Honey, Partnership, VP, University, Excellent, Workforce, CEO, Technology, GFS, JVP, Tobacco, Hebrew University of Jerusalem, Smoking, NASDAQ, Doctor of Philosophy, Natural Resources, VC, The Good Food Institute, Financial technology, Farmer, Preqin, Center, Food security, MBA, Bioreactor, Insulin, Milk, IIA, GF, A-DNA, FGF2, LLC, Meat, Ecosystem, Israel Innovation Authority, Industry, Transferrin, Institution, AI, Jerusalem Venture Partners, Income, Agriculture, Renewable energy, Fine chemical, MD

KIRYAT SHEMONA, Israel, Sept. 7, 2022 /PRNewswire/ -- FoodTech start-up BioBetter, Ltd., has secured USD10M in its A –round funding. The round was led by Jerusalem Venture Partners (JVP), with additional investment from Milk and Honey Investments, LLC, and the Israeli Innovation Authority (IIA). This significant injection of capital will be instrumental in accelerating cell-cultured meat closer to its ambitions for broad scale production.

Key Points: 
  • BioBetter harnesses the inherent advantages of tobacco plants as bioreactors for creating the growth factors necessary for the cellular development of cultivated meat.
  • BioBetter has pioneered a unique protein manufacturing platform for producing growth factors (GFs) using tobacco plants (Nicotiana tabacum) as natural, self-sustaining, animal-free bioreactors.
  • The field-grown tobacco plants offer a new, sustainable, efficient, and flexible response to the market need for more competitively priced GFs, specifically insulin, transferrin, and FGF2.
  • "Thanks to the Biobetter platform, tobacco is set to make a pivotal comeback as a catalyst for bringing better food security," adds Dana Yarden, MD, co-founder of BioBetter.

RIBOMIC Announces Completion of IND Submission for an Observational Study for Continuous Phase 2 Trial of RBM-007 for Treatment of Achondroplasia

Retrieved on: 
星期二, 四月 19, 2022
Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Other Health, Ministry of Health, Labour and Welfare, Aptamer, Adult, Chondrocyte, Ageing, Research, Achondroplasia, FGF2, Ministry, Growth, Ministry of Health and Medical Education, Company, Advertising, Safety, Fibroblast, Disease, Therapy, Pharmaceutical industry, Health, FGFR3

RBM-007 has been shown to have potent effects in limiting excessive interactions between fibroblast growth factors, which are known to cause achondroplasia.

Key Points: 
  • RBM-007 has been shown to have potent effects in limiting excessive interactions between fibroblast growth factors, which are known to cause achondroplasia.
  • Achondroplasia is a rare disease characterized by short stature (adult height of approximately 130 cm for males and approximately 125 cm for females) with short limbs.
  • Achondroplasia has no known cure, and is designated as an intractable disease by the Ministry of Health, Labour and Welfare in Japan.
  • "RIBOMIC," "RiboART system" and the RIBOMIC logo are registered trademarks or trademarks of RIBOMIC Inc. in various jurisdictions.

RIBOMIC Inc. Provides Update on RBM-007 Program in Wet Age-Related Macular Degeneration

Retrieved on: 
星期三, 三月 23, 2022
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, IST, Company, Blood, Advertising, Therapy, TOFU, AMD, OCT, Doctor of Philosophy, Standard of care, CEO, Retina, Visual acuity, Safety, Retinal degeneration, CST, Severe cognitive impairment, Growth factor, FGF2, Fibrosis, Patient, Choroidal neovascularization, Pharmaceutical industry, Medical imaging, RBM-007, WET AGE-RELATED MACULAR DEGENERATION

At month 3, the subject gained 12 letters and the subjects BCVA continued to improve without further treatment.

Key Points: 
  • At month 3, the subject gained 12 letters and the subjects BCVA continued to improve without further treatment.
  • RBM-007 provides a unique approach to the treatment of wet AMD with clinically relevant and meaningful improvements in some subjects with nave wet AMD.
  • Wet (exudative) age-related macular degeneration, is the leading cause of blindness in the United States and Europe.
  • "RIBOMIC," "RiboART system" and the RIBOMIC logo are registered trademarks or trademarks of RIBOMIC Inc. in various jurisdictions.

Aurealis Therapeutics and Xbiome Enter into a License and Collaboration Agreement for Aurealis Four-in-One Diabetic Foot Ulcer and Inflammatory Disease Cell and Gene Therapy AUP-16 in Greater China

Retrieved on: 
星期五, 一月 28, 2022
Lynx, Aurealis, Growth, IND, CEO, Patient, Therapy, Graft-versus-host disease, FGF2, CSF1, GMO, FMT, Inflammation, Board, Human microbiome, Partnership, Granulation tissue, Prevalence, Growth factor, DFU, IL4, Company, Interleukin, Lactococcus lactis, Drug development, Blood, Mouth ulcer, Synthetic biology, LBP, Diabetic foot ulcer, Scholarship, Pharmaceutical industry, Vaccine

"At Aurealis we develop truly novel GMO cell and gene therapies to improve the lives of millions of patients worldwide.

Key Points: 
  • "At Aurealis we develop truly novel GMO cell and gene therapies to improve the lives of millions of patients worldwide.
  • We are extremely excited to collaborate with Aurealis to bring AUP-16 to DFU and other chronic wound patients in China.
  • Company's lead clinical asset is AUP-16, the first-in-class four-in-one cell and gene therapy drug for chronic wounds and other inflammatory degenerative diseases.
  • In June of 2021, Xbiome obtained IND approval in US for its lead program XBI-302, an orally administered FMT therapy for graft-versus-host disease (GvHD).